A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
AIMS: Despite the growing interest in the broad applications of semaglutide, real-world data on its use in weight-loss is limited. This study aims to explore the pattern of semaglutide prescriptions in a Canadian family medicine practice. METHODS: Th…
BACKGROUND: In recent years, there has been a dramatic increase in the popularity and use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. As such, it is essential to understand users' real-world discussions of short-term, lo…
BACKGROUND: Clinical experience with semaglutide in patients with type 2 diabetes mellitus shows that its benefits extend far beyond glucose regulation. This study examines whether this drug is indeed popular among the Croatian population and explore…
PURPOSE OF REVIEW: This review explores the integration of semaglutide, a highly effective glucagon-like peptide-1 receptor agonist (GLP-1RA), with medical nutritional therapy (MNT) for the comprehensive management of obesity. Semaglutide promotes si…
Diabetes and mood disorders are intricately interconnected, with each condition elevating the risk of the other. This bidirectional relationship, further exacerbated by neuroinflammation, fosters an environment conducive to the development of anxiety…
Introduction This study aims to evaluate the risk of residual gastric content (RGC) among patients taking semaglutide/tirzepatide undergoing an esophagogastroduodenoscopy (EGD). Methods A retrospective observational study was conducted from 2024 to 2…
INTRODUCTION: This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimburs…
Parkinson's disease demonstrates increased iron concentration in the substantia nigra (SN). The progression of iron and its interaction with neuromelanin content and dopaminergic dysregulation from prodromal to early-stage Parkinson's disease remain…
OBJECTIVE: To characterize the weight fluctuation and explore its influencing factors after glucagon-like peptide 1 receptor agonist (GLP-1RA) treatment in patients with overweight or obesity. METHODS: This retrospective cohort study enrolled 679 pat…
Peptide therapeutics are rapidly emerging as a new drug modality, bridging the gap between small molecules and biologics to target diseases such as diabetes, cancer, and cardiovascular disorders. Despite their advantages, challenges like metabolic in…
PURPOSE: This study aimed to evaluate the effects of semaglutide (Ozempic) on glycemic control and body weight in patients with type 2 diabetes in a primary care setting. Additionally, the rate of discontinuation due to adverse effects was assessed.…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are FDA-approved for weight loss and are increasingly prescribed for patients with obesity and type 2 diabetes mellitus. Multiple studies have demonstrated desirable renal and cardiov…
The rising prevalence of youth-onset type 2 diabetes (T2D) in children necessitates early intervention with tight glycemic control, obesity medications, and metabolic and bariatric surgery (MBS). Insulin and metformin are standard treatments, but add…